The Missing Piece: Why Healthy Longevity Needs a Standard

The Missing Piece: Why Healthy Longevity Needs a Standard

‍

By Renée-Marie Stephano, Chief Executive Officer, Global Healthcare Accreditation

‍

‍

In the first article in this series, I argued that longevity is the gateway through which patients and institutions are entering a much larger conversation about healthspan. In the second, I looked at what that shift requires operationally: connecting prevention and clinical care, integrating information, designing the handoffs between them, aligning incentives, and measuring function over time rather than simply counting clinical activity.

‍

There is a third question that follows naturally from both arguments. If healthy longevity is developing into a legitimate area of clinical practice, what should distinguish a credible longevity medicine program from the increasingly broad collection of services now being marketed under the same name?

‍

This is not an abstract concern. Longevity medicine is developing at an unusual intersection of established medicine, preventive health, lifestyle medicine, diagnostics, emerging biotechnology, and consumer demand. Some of what sits within that landscape is supported by substantial clinical evidence. Some is promising but remains under investigation. Some has limited evidence for the claims being made around it. The distinctions are important, particularly when patients may have difficulty making them for themselves.

‍

The field therefore faces a challenge familiar to other areas of medicine as they mature: innovation needs room to develop, but the infrastructure for evaluating and delivering innovation responsibly has to develop with it.

‍

‍

Defining What a Longevity Medicine Program Is

‍

One of the first issues we encountered in developing GHA's longevity medicine standards was definitional. It is surprisingly easy to describe an organization as a longevity clinic and considerably more difficult to define what should qualify as a comprehensive longevity medicine program.

The distinction cannot simply be the presence of particular services. IV therapies, supplements, hormone management, peptide therapies, biological-age testing, advanced diagnostics, and other technologies may appear within longevity programs, but their availability does not by itself establish a coherent model of longevity medicine.

‍

A more defensible starting point is the clinical system surrounding those services: physician leadership, comprehensive assessment, appropriate diagnostic use, individualized and longitudinal care planning, lifestyle and preventive medicine, evidence-informed clinical decision-making, informed consent, monitoring, referral pathways, and measurement of outcomes over time.

‍

That definition also places healthspan back where I believe it belongs in this discussion. The objective is not simply to accumulate interventions intended to influence aging. It is to preserve health and function for as long as possible through an integrated approach to prevention and clinical care.

‍

This is also why the distinction between longevity and healthspan that began this series matters. Longevity may be the language bringing patients into the field, but healthspan provides a more disciplined framework for asking what the field is trying to accomplish.

‍

‍

The More Difficult Question Is Evidence

‍

Defining the clinical model is only the beginning. A credible standard for longevity medicine must also confront the considerable variation in evidence across the field.

‍

This is where accreditation has to be careful about its own role.

‍

An accrediting organization should not determine that a particular intervention is effective simply because an accredited clinic provides it. Nor should accreditation be interpreted as regulatory approval, scientific endorsement, or a substitute for clinical judgment. Doing so would risk giving institutional credibility to a scientific claim that the accreditation process itself is not designed to establish.

‍

The more appropriate role is to evaluate the systems through which evidence is classified, interpreted, disclosed, and translated into clinical practice.

‍

That means asking whether an organization can distinguish established interventions from those supported by more limited evidence; whether patients understand when an intervention is emerging or investigational; whether diagnostic and biological-age technologies are being used within their validated limitations; whether conflicts of interest could influence recommendations; whether adverse events and outcomes are being followed; and whether public claims accurately reflect the underlying science.

‍

These are not peripheral quality questions. In an emerging field, they are central to patient protection and ultimately to the credibility of the field itself.

‍

‍

There Also Have to Be Boundaries

‍

This has been an important evolution in our own thinking as we have developed the standards.

It is not sufficient for every intervention to be permissible provided that an organization has a policy governing it. Some practices may have a place within appropriately governed research, while not yet having an adequate basis to be marketed as established longevity medicine. Others may fall outside an acceptable clinical scope altogether.

‍

That requires a standards framework to do something more difficult than ask whether an organization has documented its processes. It must establish boundaries around what accreditation does and does not encompass, while retaining a mechanism for those boundaries to evolve as the evidence changes.

‍

The same principle applies to evidence classification. The credibility of the system depends upon an accredited organization not being able to determine for itself how strongly the evidence supports the interventions it sells. The emerging GHA framework is therefore being designed around independent evidence classification and explicit disclosure of the level and limitations of evidence associated with interventions within scope.

‍

This is an area in which continued engagement with researchers, clinicians, professional organizations, and other experts in healthy longevity medicine is particularly important. Standards in a developing field should be sufficiently rigorous to establish meaningful boundaries, but they also need a governance structure capable of responding as the science develops.

‍

‍

Measurement May Ultimately Be as Important as Accreditation

‍

There is another issue that becomes apparent once healthspan is treated as the objective: accreditation cannot stop at organizational structure and process.

‍

If an organization claims to be delivering care intended to preserve function and extend healthspan, then over time the field needs to become better at measuring whether it is doing so.

‍

That is difficult. Healthspan is longitudinal by definition, and many of the outcomes that matter will take years to understand. Biomarkers of aging are developing rapidly, but they should not be confused with validated clinical outcomes simply because they can produce an apparently precise number.

‍

This makes longitudinal data increasingly important. A mature healthy longevity ecosystem should ultimately be capable not only of evaluating whether organizations have appropriate systems, but also of generating standardized information that helps the field understand outcomes, safety, and effectiveness across populations.

‍

I believe accreditation can contribute to that infrastructure because it creates something research alone often cannot: a common set of expectations across otherwise independent organizations. Whether that eventually supports broader registries, benchmarking, or other collaborative research structures is an important question, and one that should be developed with the scientific community rather than predetermined by the accreditor.

‍

That distinction matters. Accreditation can provide the mechanism for standardized participation. Scientific questions about what should be measured, how those data should be analyzed, and what conclusions can appropriately be drawn from them belong within appropriate scientific governance.

‍

‍

From a Standard to a Framework for Excellence

‍

It is against this background that GHA has been developing GHA Longevity Medicine Accreditation™, which we describe as The Gold Standard for Longevity Medicine™.

‍

The program is intended for comprehensive, physician-led healthy longevity medicine organizations and builds from core clinical practice into additional requirements particular to longevity medicine. The standards address governance, patient assessment, diagnostic and biomarker use, evidence classification, clinical interventions, informed consent, patient safety, conflicts of interest, claims, longitudinal care, outcomes, and continuous improvement.

‍

We are also developing Excellence in Longevity Medicine™ as an advanced level within this framework, with a longer-term pathway toward Center of Excellence in Longevity Medicine™ for organizations able to demonstrate sustained performance against more advanced expectations.

I think it is important to be deliberate about that distinction. A Center of Excellence should not be a title an organization acquires simply by completing an accreditation process. If the designation is to have meaning, it should ultimately reflect demonstrated performance and mature capability, informed by what we learn as the first organizations move through the standards.

‍

This is one reason we view the current stage as the beginning of the accreditation program rather than the completion of it.

‍

‍

An Additional Question: Can the Model Scale Responsibly?

‍

There is also an organizational dimension that we have incorporated into the broader architecture through Enterprise Readiness™.  

‍

It is intentionally secondary to the clinical and scientific questions. An organization should not become “enterprise ready” before it is clinically and scientifically credible.

‍

But if healthy longevity medicine is eventually going to move beyond a predominantly private-pay model, organizations will need to demonstrate that they can work responsibly with health systems, employers, insurers, and other institutional partners. That introduces additional requirements around governance, data, privacy, contracting, clinical independence, reporting, and operational resilience.

‍

This may become important to the accessibility of healthy longevity medicine over time. The field will have limited population impact if its benefits remain available primarily through high-cost individual programs. But the path toward broader access has to begin with scientific and clinical credibility, not with distribution.

‍

‍

Where the Work Stands

‍

GHA is now moving the Longevity Medicine Accreditation™ framework into its next stage of development and early implementation. We are finalizing discussions with a limited number of organizations while continuing scientific and professional engagement around several elements of the framework.

‍

I think that is the appropriate way to introduce a standard in a field that is itself still evolving.

The purpose of accreditation should not be to settle scientific questions that remain unsettled. It should create a disciplined environment in which those distinctions are respected: where established evidence is distinguished from emerging evidence, where research is not presented as routine clinical practice, where patients can understand the limitations of what is being offered, and where organizations are accountable for the claims they make and the outcomes they measure.

‍

There is still work to do, and there should be. A standard intended to contribute to the credibility of healthy longevity medicine should be willing to develop alongside the science and to be challenged by the clinicians, researchers, and organizations working seriously in the field.

‍

The first article in this series argued that longevity is the gateway and healthspan the destination. The second considered what an organization must build to connect the two. This third step is about establishing the framework through which that work can be evaluated independently and improved over time.

‍

For me, that is the appropriate role of accreditation at this stage of healthy longevity medicine: not to confer scientific legitimacy, but to create the conditions in which scientific rigor, responsible clinical practice, transparency, and measurable improvement can be expected of the organizations seeking to lead the field.

‍